Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?

Clapham, John C (2020) Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now? In: Type 2 Diabetes Methods and Protocols : methods in molecular biology. Humana Press, New York, pp. 1-30. ISBN 9781493998807

[img] Text
__TAIPAN_john.clapham_Documents_002 SCIENCE_BOOK CHAPTER_BOOK CHAPTER CLAPHAM.pdf
Restricted to Registered users only until 31 January 2022.

Download (346kB) | Request a copy
Official URL: https://link.springer.com/protocol/10.1007/978-1-4...

Abstract

The control of blood glucose is a dynamic interplay involving several complex systems. In diabetes these systems are perturbed, resulting in a disease continuum of progressive decline over many years. Today, excluding insulin, there are eight classes of anti-diabetic agent which have taken over 60 years to add to the pharmacy chest. In this review I have examined each of these classes with some bias towards drug discovery thinking. Based on history, future science here will be strong, progressive and innovative; the huge test for industry is their response to enormous challenges besetting drug discovery and successfully turn the drug discovery praxis into affordable, effective and safe medicines.

Item Type: Book Section
Uncontrolled Keywords: Type-2-diabetes Drug discovery Metformin Sulfonylureas Biguanides Thiazolidinediones α-Glucosidase inhibitors DPPIV inhibitors GLP-1 SGLT2 inhibitors Pharmaceutical industry
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: School of Science > Metabolic Research
Depositing User: John Clapham
Date Deposited: 10 Mar 2020 15:02
Last Modified: 10 Mar 2020 15:02
URI: http://bear.buckingham.ac.uk/id/eprint/443

Actions (login required)

View Item View Item